This research study is being done to learn more about multiple myeloma and if the study drug, GSK2857916, can improve multiple myeloma in patients who have already failed other treatments. We also would like to answer the following questions:
Some parts of this study are research which means they have not been tested yet.
Please note that GSK2857916 is not yet approved for use in people with multiple myeloma.
SparkCures ID | 953 |
---|---|
Trial Phase | Phase 2 |
Enrollment | 155 Patients |
Treatments | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersRead the latest news and updates on this trial.